{"pmid":32479824,"title":"Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.","text":["Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients with Inflammatory Bowel Disease.","Gastroenterology","Lukin, Dana J","Kumar, Anand","Hajifathalian, Kaveh","Sharaiha, Reem Z","Scherl, Ellen J","Longman, Randy S","32479824"],"journal":"Gastroenterology","authors":["Lukin, Dana J","Kumar, Anand","Hajifathalian, Kaveh","Sharaiha, Reem Z","Scherl, Ellen J","Longman, Randy S"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479824","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1053/j.gastro.2020.05.066","keywords":["biologic therapy","covid-19","ibd","sars-cov-2"],"topics":["Treatment","Prevention","Diagnosis"],"weight":1,"_version_":1668437835142660096,"score":9.490897,"similar":[{"pmid":32360811,"pmcid":"PMC7191273","title":"Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts.","text":["Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts.","Clin Gastroenterol Hepatol","Allocca, Mariangela","Fiorino, Gionata","Zallot, Camille","Furfaro, Federica","Gilardi, Daniela","Radice, Simona","Danese, Silvio","Peyrin-Biroulet, Laurent","32360811"],"journal":"Clin Gastroenterol Hepatol","authors":["Allocca, Mariangela","Fiorino, Gionata","Zallot, Camille","Furfaro, Federica","Gilardi, Daniela","Radice, Simona","Danese, Silvio","Peyrin-Biroulet, Laurent"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360811","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cgh.2020.04.071","keywords":["covid-19","biologic therapy","immunosuppressants","inflammatory bowel disease"],"locations":["Nancy","Milan"],"countries":["Italy","France"],"countries_codes":["ITA|Italy","FRA|France"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495896256512,"score":122.400536},{"pmid":32283100,"pmcid":"PMC7151253","title":"AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.","text":["AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.","DESCRIPTION: The purpose of this AGA Institute Clinical Practice Update is to rapidly review the emerging evidence and provide timely expert recommendations regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. METHODS: This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology.","Gastroenterology","Rubin, David T","Feuerstein, Joseph D","Wang, Andrew Y","Cohen, Russell D","32283100"],"abstract":["DESCRIPTION: The purpose of this AGA Institute Clinical Practice Update is to rapidly review the emerging evidence and provide timely expert recommendations regarding the management of patients with inflammatory bowel disease during the COVID-19 pandemic. METHODS: This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology."],"journal":"Gastroenterology","authors":["Rubin, David T","Feuerstein, Joseph D","Wang, Andrew Y","Cohen, Russell D"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32283100","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1053/j.gastro.2020.04.012","keywords":["coronavirus","crohn's disease","ibd","immunosuppression","sars-cov-2","ulcerative colitis"],"topics":["Prevention"],"weight":1,"_version_":1666138491534180352,"score":95.50228},{"pmid":32360133,"pmcid":"PMC7151446","title":"Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak.","text":["Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak.","Coronavirus disease 2019 has been recently classified as pandemic infection by the World Health Organization. Patients with inflammatory bowel disease (IBD) are invited to follow the national recommendations as any other person. It is unclear whether a more aggressive clinical course might develop in asymptomatic COVID-19 infected subjects during biological therapy and current evidence does not support treatment suspension. However, during pandemic, the start of treatment with immunosuppressive drugs and biologics should be postponed whenever possible and based on an individual risk assessment. When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. Serum antibody testing, when available, could provide evidence of infection as well as identify patients already immune to the disease.","Dig Liver Dis","Zingone, Fabiana","Buda, Andrea","Savarino, Edoardo Vincenzo","32360133"],"abstract":["Coronavirus disease 2019 has been recently classified as pandemic infection by the World Health Organization. Patients with inflammatory bowel disease (IBD) are invited to follow the national recommendations as any other person. It is unclear whether a more aggressive clinical course might develop in asymptomatic COVID-19 infected subjects during biological therapy and current evidence does not support treatment suspension. However, during pandemic, the start of treatment with immunosuppressive drugs and biologics should be postponed whenever possible and based on an individual risk assessment. When clinical conditions and the disease activity do not allow a treatment delay, before starting a biological therapy, screening of IBD patients for COVID-19 active infection by RT-PCR should be advisable, even in absence of clinical suspicion. Serum antibody testing, when available, could provide evidence of infection as well as identify patients already immune to the disease."],"journal":"Dig Liver Dis","authors":["Zingone, Fabiana","Buda, Andrea","Savarino, Edoardo Vincenzo"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360133","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.dld.2020.04.004","keywords":["biologic","covid-19","crohn's disease","ibd","ulcerative colitis","screening"],"topics":["Prevention"],"weight":1,"_version_":1666138495529254913,"score":72.51741},{"pmid":32354990,"title":"Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.","text":["Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.","OBJECTIVES: COVID-19 has rapidly become a major health emergency worldwide. Patients with IBD are at increased risk of infection, especially when they have active disease and are taking immunosuppressive therapy. The characteristics and outcomes of COVID-19 in patients with IBD remain unclear. DESIGN: This Italian prospective observational cohort study enrolled consecutive patients with an established IBD diagnosis and confirmed COVID-19. Data regarding age, sex, IBD (type, treatments and clinical activity), other comorbidities (Charlson Comorbidity Index (CCI)), signs and symptoms of COVID-19 and therapies were compared with COVID-19 outcomes (pneumonia, hospitalisation, respiratory therapy and death). RESULTS: Between 11 and 29 March 2020, 79 patients with IBD with COVID-19 were enrolled at 24 IBD referral units. Thirty-six patients had COVID-19-related pneumonia (46%), 22 (28%) were hospitalised, 7 (9%) required non-mechanical ventilation, 9 (11%) required continuous positive airway pressure therapy, 2 (3%) had endotracheal intubation and 6 (8%) died. Four patients (6%) were diagnosed with COVID-19 while they were being hospitalised for a severe flare of IBD. Age over 65 years (p=0.03), UC diagnosis (p=0.03), IBD activity (p=0.003) and a CCI score >1 (p=0.04) were significantly associated with COVID-19 pneumonia, whereas concomitant IBD treatments were not. Age over 65 years (p=0.002), active IBD (p=0.02) and higher CCI score were significantly associated with COVID-19-related death. CONCLUSIONS: Active IBD, old age and comorbidities were associated with a negative COVID-19 outcome, whereas IBD treatments were not. Preventing acute IBD flares may avoid fatal COVID-19 in patients with IBD. Further research is needed.","Gut","Bezzio, Cristina","Saibeni, Simone","Variola, Angela","Allocca, Mariangela","Massari, Alessandro","Gerardi, Viviana","Casini, Valentina","Ricci, Chiara","Zingone, Fabiana","Amato, Arnaldo","Caprioli, Flavio","Lenti, Marco Vincenzo","Vigano, Chiara","Ascolani, Marta","Bossa, Fabrizio","Castiglione, Fabiana","Cortelezzi, Claudio","Grossi, Laurino","Milla, Monica","Morganti, Daniela","Pastorelli, Luca","Ribaldone, Davide Giuseppe","Sartini, Alessandro","Soriano, Alessandra","Manes, Gianpiero","Danese, Silvio","Fantini, Massimo","Armuzzi, Alessandro","Daperno, Marco","Fiorino, Gionata","32354990"],"abstract":["OBJECTIVES: COVID-19 has rapidly become a major health emergency worldwide. Patients with IBD are at increased risk of infection, especially when they have active disease and are taking immunosuppressive therapy. The characteristics and outcomes of COVID-19 in patients with IBD remain unclear. DESIGN: This Italian prospective observational cohort study enrolled consecutive patients with an established IBD diagnosis and confirmed COVID-19. Data regarding age, sex, IBD (type, treatments and clinical activity), other comorbidities (Charlson Comorbidity Index (CCI)), signs and symptoms of COVID-19 and therapies were compared with COVID-19 outcomes (pneumonia, hospitalisation, respiratory therapy and death). RESULTS: Between 11 and 29 March 2020, 79 patients with IBD with COVID-19 were enrolled at 24 IBD referral units. Thirty-six patients had COVID-19-related pneumonia (46%), 22 (28%) were hospitalised, 7 (9%) required non-mechanical ventilation, 9 (11%) required continuous positive airway pressure therapy, 2 (3%) had endotracheal intubation and 6 (8%) died. Four patients (6%) were diagnosed with COVID-19 while they were being hospitalised for a severe flare of IBD. Age over 65 years (p=0.03), UC diagnosis (p=0.03), IBD activity (p=0.003) and a CCI score >1 (p=0.04) were significantly associated with COVID-19 pneumonia, whereas concomitant IBD treatments were not. Age over 65 years (p=0.002), active IBD (p=0.02) and higher CCI score were significantly associated with COVID-19-related death. CONCLUSIONS: Active IBD, old age and comorbidities were associated with a negative COVID-19 outcome, whereas IBD treatments were not. Preventing acute IBD flares may avoid fatal COVID-19 in patients with IBD. Further research is needed."],"journal":"Gut","authors":["Bezzio, Cristina","Saibeni, Simone","Variola, Angela","Allocca, Mariangela","Massari, Alessandro","Gerardi, Viviana","Casini, Valentina","Ricci, Chiara","Zingone, Fabiana","Amato, Arnaldo","Caprioli, Flavio","Lenti, Marco Vincenzo","Vigano, Chiara","Ascolani, Marta","Bossa, Fabrizio","Castiglione, Fabiana","Cortelezzi, Claudio","Grossi, Laurino","Milla, Monica","Morganti, Daniela","Pastorelli, Luca","Ribaldone, Davide Giuseppe","Sartini, Alessandro","Soriano, Alessandra","Manes, Gianpiero","Danese, Silvio","Fantini, Massimo","Armuzzi, Alessandro","Daperno, Marco","Fiorino, Gionata"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354990","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1136/gutjnl-2020-321411","keywords":["ibd","epidemiology"],"locations":["Italian","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138495224119296,"score":72.3076},{"pmid":32359205,"title":"2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases.","text":["2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases.","BACKGROUND: Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are lacking. AIM: To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD. METHODS: This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region. RESULTS: Through April 8, 12 patients of 1918 IBD patients were diagnosed of COVID-19. The average age was 52 years, 75% of the patients were female, and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these 4 with combined therapy (33%). Eight patients (66%) required hospitalization (1 intensive care unit admission, and 2 deaths), and 4 patients were isolated at home. Nine patients had diarrhoea ranging between 4-10 loose stools per day (mean 5.4, SD 1.6). In 5 patients (42%) diarrhoea was a presenting symptom. In 2 patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.1 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; p<0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; p=0.36), compared with the general population. CONCLUSIONS: IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19.","Aliment Pharmacol Ther","Taxonera, Carlos","Sagastagoitia, Inigo","Alba, Cristina","Manas, Norberto","Olivares, David","Rey, Enrique","32359205"],"abstract":["BACKGROUND: Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS-CoV-2) disease (COVID-19) are lacking. AIM: To report the clinical characteristics, including gastrointestinal symptoms, of COVID-19 in IBD patients, and to assess the risk of COVID-19 in IBD. METHODS: This case series included consecutive IBD patients with laboratory-confirmed COVID-19. Age-adjusted cumulative incidences were compared with the general population in the Madrid region. RESULTS: Through April 8, 12 patients of 1918 IBD patients were diagnosed of COVID-19. The average age was 52 years, 75% of the patients were female, and 58.3% had Crohn's disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these 4 with combined therapy (33%). Eight patients (66%) required hospitalization (1 intensive care unit admission, and 2 deaths), and 4 patients were isolated at home. Nine patients had diarrhoea ranging between 4-10 loose stools per day (mean 5.4, SD 1.6). In 5 patients (42%) diarrhoea was a presenting symptom. In 2 patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID-19 was 6.1 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID-19 (OR 0.74, 95% CI 0.70-0.77; p<0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84-1.06; p=0.36), compared with the general population. CONCLUSIONS: IBD patients do not have an increased risk of COVID-19 and associated mortality compared with the general population. In many IBD patients diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID-19."],"journal":"Aliment Pharmacol Ther","authors":["Taxonera, Carlos","Sagastagoitia, Inigo","Alba, Cristina","Manas, Norberto","Olivares, David","Rey, Enrique"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359205","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/apt.15804","keywords":["covid-19","sars-cov-2","diarrhoea","inflammatory bowel disease"],"locations":["Madrid"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495306956801,"score":71.53802}]}